Osteotech, Inc. is a global leader in the processing of human bone and connective tissue for transplantation and an innovator in the development, manufacturing and marketing of biologic, biomaterial and device systems for musculoskeletal surgery. With a particular focus on spinal, trauma, and total joint revision procedures, the Company's current and development-stage technologies address needs within numerous musculoskeletal disciplines.
Our strategy leverages our core competency in biological sciences, to fulfill unmet clinical needs of the worldwide orthopaedic surgical community. As a technology leader in orthobiologics, we focus on creating and redefining select orthopaedic market segments through the application of innovative regeneration technologies. Additionally, we have business alliances and product development initiative that are aimed at providing a broad base of unique non-biologic technologies that work in concert with our biologically active tissue forms. The combination of these technology platforms, coupled with our distribution network, offer the potential for consistent revenue and pre-tax profit growth. Since its formation in 1986, the Company has become the world's largest processor of aseptic allograft bone tissue yielding over 4.5 million grafts. Used in spinal fusions, to replace cancerous tissue, fill voids caused by trauma, augment prostheses and replace damaged ligaments and tendons, bone tissues processed by Osteotech improve the quality of life for more than 500 transplant recipients every day. In addition, the Company has acquired 90% of OST Developpement in France, which will enable the Company to expand its allograft business throughout Western Europe.
Osteotech continues to develop a series of human tissue technologies for use in musculoskeletal surgery. The first such technology, Grafton® Demineralized Bone Matrix (DBM) Gel, was introduced in mid-1991. Grafton Gel is demineralized allograft bone that is processed into a proprietary gel-like consistency and provided in sterile single-patient delivery containers. Grafton® DBM Flex, a proprietary pliable form of DBM, was introduced in January 1996; Grafton® DBM Putty, a moldable, putty-like form of DBM, was introduced in November 1996. Two new forms, Grafton® DBM Crunch for graft site support and Grafton® DBM Matrix PLF, for posterolateral spine fusions, have also recently been added to the Grafton® DBM line. These new forms. like Flex and Putty, are made from bone fibers, not particles. Osteotech is the only company to produce DBM from bone fibers. All Grafton® DBM forms help form bone through osteoconduction and osteoinduction and are processed in a manner that has been scientifically validated to be a viral inactivation process. To date, the Company's Grafton® DBM forms have been used in over 400,000 surgical procedures by more than 4,000 transplant professionals, worldwide.
In 2000, the Company developed and launched four new Graftech® structural allograft systems, which incorporate Osteotech's proprietary processing technologies. Osteotech entered the rapidly expanding cervical market with two unique grafts, Graftech® Cervical Spacer and Graftech® Cervical Dowel, both processed from select dense, cancellous tissue. In addition, the Company's lumbar offerings include the Graftech® Posterior Ramp and Graftech® Anterior Ramp, featuring OsteoActive® surfaces demonstrated to promote bone formation. The Company continues to develop new technologies to benefit patients as well as maximize the gift of donation.
A public company since 1991, Osteotech maintains its executive offices at 51 James Way, Eatontown, New Jersey, 07724, U.S.A., telephone (732) 542-2800.